Literature DB >> 2161823

Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats.

B Kreft1, C de Wit, R Krech, R Marre, E Schulz, K Sack.   

Abstract

The nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) were studied in an experimental rat model. Nephrotoxicity was assessed by measuring urinary loss of tubular cells and malate dehydrogenase. LY 146032 (10-250 mg/kg daily iv) led to a dose-dependent and reversible increase of cell elimination. The tubulo-toxic threshold dose is stated to be 10 mg/kg daily. Nephrotoxicity induced by LY 146032 can be reduced by coadministration of fosfomycin or D-glucaro-1.5-lactam, and enhanced by combination with tobramycin. LY 146032 accumulated in renal tissue during repeated administration. Electron microscopy revealed histopathological changes in the kidneys. Therefore the nephrotoxic potential of LY 146032 should be taken into consideration in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161823     DOI: 10.1093/jac/25.4.635

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.

Authors:  Romain Garreau; Damien Montange; Antoine Grillon; François Jehl; Tristan Ferry; Laurent Bourguignon; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2022-08-16       Impact factor: 5.577

2.  Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin.

Authors:  M Couture; M Simard; P Gourde; C Lessard; K Gurnani; L Lin; D Carrier; M G Bergeron; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

3.  Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.

Authors:  Joseph S Bubalo; Myrna Y Munar; Ganesh Cherala; Brandon Hayes-Lattin; Richard Maziarz
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

4.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.

Authors:  J R Woodworth; E H Nyhart; G L Brier; J D Wolny; H R Black
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity.

Authors:  N Thibault; L Grenier; M Simard; M G Bergeron; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 6.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

Review 7.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.